Comorbidities in Cushing’s disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Cushing's disease is a rare disorder characterized by overproduction of ACTH from a pituitary adenoma leading to hypercortisolemia that in turn leads to increased morbidity and mortality. METHODS: Here we review the comorbidities associated with Cushing's disease and their impact on quality of life and mortality. RESULTS: Recent evidence suggests that correction of hypercortisolemia may not lead to complete resolution of comorbidities associated with this condition. In particular, increased cardiovascular risk may persist despite long-term remission of hypercortisolemia. This may be related to persistence of visceral adiposity, adverse adipokine profile, glucose intolerance, hypertension, dyslipidemia, atherosclerosis and a procoagulant phenotype. Prior prolonged exposure to glucocorticoids also may have irreversible effects on the central nervous system, leading to persistent cognitive and mood alterations. Osteoporosis and fractures, especially vertebral fractures, can further add to morbidity and a poor quality of life. Normalization of cortisol levels leads to significant improvement in comorbidities but long-term data regarding complete resolution are lacking and need further study. CONCLUSION: Early diagnosis and treatment of hypercortisolemia, aggressive management of comorbidities along with long-term follow-up is crucial for the optimal recovery of these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Starkman, M. N., Gebarski, S. S., Berent, S., & Schteingart, D. E. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90079-f · Cited by 840 · cited 4×
“Cognitive impairment [47–53]”
BackgroundInfluentialMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease
Starkman, M. N., Giordani, B., Gebarski, S. S., Berent, S., Schork, M. A., & Schteingart, D. E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00203-6 · Cited by 455 · cited 2×
“In one study, the issues most often reported by CS patients with regards to the impact of the disease on their everyday life were fatigue and weakness (85 %), interference with family life and relationship with their partners (80 %), changes in physical appearance (63 %), emotional instability (61 %), impaired school/…”
BackgroundValassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C. J., Chanson, P., Wass, J. A. H., Chabre, O., Pfeifer, M., Feelders, R. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0272 · Cited by 402 · cited 1×
“rib fractures is significantly higher in men compared to women [5].”
BackgroundSelf-citationFaggiano, A., Pivonello, R., Spiezia, S., De Martino, M. C., Filippella, M., Di Somma, C., Lombardi, G., & Colao, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021558 · Cited by 358
High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278 · cited 5×
“Hypertension occurs in 55–85 % of CD patients [11, 15, 16], but resolves after remission in only 44–75 % [14, 16, 17].”
BackgroundInfluentialDorn, L. D., Burgess, E. S., Friedman, T. C., Dubbert, B., Gold, P. W., & Chrousos, G. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3834 · Cited by 260 · cited 3×
“Overall psychopathology 67 % [42, 45]”
BackgroundHypercoagulable State in Cushing’s Syndrome: A Systematic Review
Van Zaane, B., Nur, E., Squizzato, A., Dekkers, O. M., Twickler, M. (. B., Fliers, E., Gerdes, V. E. A., Büller, H. R., & Brandjes, D. P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0290 · Cited by 216
Lindsay, J. R., Nansel, T., Baid, S., Gumowski, J., & Nieman, L. K. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1058 · Cited by 210
Self-citationIncidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study
Stuijver, D. J. F., van Zaane, B., Feelders, R. A., Debeij, J., Cannegieter, S. C., Hermus, A. R., van den Berg, G., Pereira, A. M., de Herder, W. W., Wagenmakers, M. A. E. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1661 · Cited by 208 · cited 3×
“surgery [27].”
InfluentialSelf-citation
Research works printed but not linked: 43
- Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. Lancet 367:1605–1617 · DOI · Paper page
- Lindholm J, Juul S, Jorgenson JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome: a population based study. J Clin Endocrinol Metab 86:117–123
- Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA (2007) Mortality in patients treated for Cushing’s disease is increased compared to patients treated for nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 92:976–981 · DOI · Paper page
- Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326 · DOI · Paper page
- Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stokeon-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632–642 · DOI · Paper page
- Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JO (2012) Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med 23(3):278–282 · DOI
- Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84(8):664–672
- Neary NM, Booker OJ, Abel BS, Matta JR, Muldoon N, Sinaii N, Pettigrew RI, Nieman LK, Gharib AM (2013) Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab 98:2045–2052 · DOI · Paper page
- Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP, Nieman LK (2007) Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res 22(1):110–118 · DOI · Paper page
- Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM (2009) Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab 94:3365–3371 · DOI · Paper page
- Fallo F, Sonino N, Barzon L, Pistorello M, Pagotto U, Paoletta A, Boscaro M (1996) Effect of surgical treatment on hypertension in Cushing’s syndrome. Am J Hypertens 9(1):77–80 · DOI · Paper page
- Gómez RM, Albiger NM, Díaz AG, Moncet D, Pitoia FA, Bruno OD (2007) Effect of hypercortisolism control on high blood pressure in Cushing’s syndrome. Medicina (B Aires) 67:439–444
- Toja PM, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati LM, Scacchi M, Parati G, Cavagnini F, Pecori Giraldi F (2012) Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin Endocrinol (Oxf) 76:332–338 · DOI
- Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, Rosei EA, Mantero F, Fallo F (2003) Left ventricular structural and functional characteristics in Cushing’s syndrome. J Am Coll Cardiol 41:2275–2279 · DOI · Paper page
- Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA (2010) Cardiac dysfunction is reversed upon successful treatment of Cushing’s syndrome. Eur J Endocrinol 162:331–340 · DOI · Paper page
- Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J Endocrinol Invest 23:145–150 · DOI
- van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Lamberts SW, Hofland LJ, Feelders RA (2012) The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 97:1303–1310 · DOI · Paper page
- Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A, Martino E (2010) Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol 163:783–791 · DOI · Paper page
- Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593 · DOI · Paper page
- Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M (2010) Pathophysiology of dyslipidemia in Cushing’s syndrome. Neuroendocrinology 92(Suppl 1):86–90 · DOI · Paper page
- Greenman Y (2010) Management of dyslipidemia in Cushing’s syndrome. Neuroendocrinology 92(Suppl 1):91–95 · DOI
- Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM (1992) Possible mechanism and treatment of o, p’DDD-induced hypercholesterolaemia. Q J Med 84:671–679
- Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–581 · DOI · Paper page
- Trementino L, Appolloni G, Ceccoli L, Marcelli G, Concettoni C, Boscaro M, Arnaldi G (2014) Bone complications in patients with Cushing’s syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos Int 25:913–921 · DOI
- Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M, Lombardi G, Colao A (2003) Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin Endocrinol (Oxf) 58:302–308 · DOI · Paper page
- Shaker JL, Lukert BP (2005) Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin N Am 34:341–356 · DOI
- Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: a prospective, long-term study. Eur J Endocrinol 154:109–118 · DOI · Paper page
- Manning PJ, Evans MC, Reid IR (1992) Normal bone mineral density following cure of Cushing’s syndrome. Clin Endocrinol (Oxf) 36:229–234 · DOI · Paper page
- Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, Corstens FH, Kloppenborg PW (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab 80:2859–2865
- Faggiano A, Pivonello R, Melis D, Filippella M, Di Somma C, Petretta M, Lombardi G, Colao A (2003) Nephrolithiasis in Cushing’s disease: prevalence, etiopathogenesis, and modification after disease cure. J Clin Endocrinol Metab 88:2076–2080 · DOI · Paper page
- Dorn LD, Burgess ES, Dubbert B, Simpson SE, Friedman T, Kling M, Gold PW, Chrousos GP (1995) Psychopathology in patients with endogenous Cushing’s syndrome: ‘atypical’ or melancholic features. Clin Endocrinol (Oxf) 43:433–442 · DOI · Paper page
- Sonino N, Fava GA (2001) Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs 15:361–373 · DOI · Paper page
- Kelly WF, Kelly MJ, Faragher B (1996) A prospective study of psychiatric and psychological aspects of Cushing’s syndrome. Clin Endocrinol (Oxf) 45:715–720 · DOI · Paper page
- Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, Gebarski SS, Langenecker SA, Starkman MN (2007) Patterns of cognitive change over time and relationship to age following successful treatment of Cushing’s disease. J Int Neuropsychol Soc 13:21–29
- Ragnarsson O, Berglund P, Eder DN, Johannsson G (2012) Long-term cognitive impairments and attentional deficits in patients with Cushing’s disease and cortisol-producing adrenal adenoma in remission. J Clin Endocrinol Metab 97:E1640–E1648 · DOI · Paper page
- Bourdeau I, Bard C, Noël B, Leclerc I, Cordeau MP, Bélair M, Lesage J, Lafontaine L, Lacroix A (2002) Loss of brain volume in endogenous Cushing’s syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 87:1949–1954
- van der Werff SJ, Andela CD, Nienke Pannekoek J, Meijer OC, van Buchem MA, Rombouts SA, van der Mast RC, Biermasz NR, Pereira AM, van der Wee NJ (2014) Widespread reductions of white matter integrity in patients with long-term remission of Cushing’s disease. Neuroimage Clin 4:659–667 · DOI · Paper page
- Gotch PM (1994) Cushing’s syndrome from the patient’s perspective. Endocrinol Metab Clin N Am 23:607–617 · DOI
- van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW, Romijn JA (2005) Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 90:3279–3286 · DOI · Paper page
- Carluccio A, Sundaram NK, Chablani S, Amrock LG, Lambert JK, Post KD, Geer EB (2014) Predictors of quality of life in 102 patients with treated Cushing’s disease. Clin Endocrinol (Oxf). doi: 10.1111/cen.12521 · DOI
- Andela CD, Scharloo M, Pereira AM, Kaptein AA, Biermasz NR (2015) Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary. doi: 10.1007/s11102-015-0636-7 · DOI
- Swearingen B, Wu N, Chen SY, Pulgar S, Biller BM (2011) Health care resource use and costs among patients with cushing disease. Endocr Pract 17:681–690 · DOI
- Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH (2014) Burden of illness, annual healthcare utilization and costs associated with commercially insured patients with Cushing’s disease in the United States. Endocr Pract. doi: 10.4158/EP14126.OR · DOI
Cited by
The multiple roles of life stress in metabolic disorders
Kivimäki, M., Bartolomucci, A., & Kawachi, I. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00746-8 · Cited by 297
The Corticotropin-Releasing Factor Family: Physiology of the Stress Response
Deussing, J. M., & Chen, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2017 · Cited by 260
Approach to the Patient: Diagnosis of Cushing Syndrome
Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac492 · Cited by 91
Self-citationNishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
“The structural changes are partially reversible with normalization of cortisol levels, but the resolution of cognitive impairment may be delayed and partial [2,3,5,45].”
BackgroundInfluentialALD1613, A Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology
Feldhaus, A. L., Anderson, K., Dutzar, B., Ojala, E., McNeill, P. D., Fan, P., Mulligan, J., Marzolf, S., Karasek, C., Scalley-Kim, M., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1455 · Cited by 32
Metadata
- Authors
- Sharma, S. T., Nieman, L. K., & Feelders, R. A.
- Venue
- Pituitary
- Published
- 2015-02-28
- Volume
- 18
- Issue
- 2
- Pages
- 188-194
- ISSN
- 1386-341X (ISSN-L)
- 1573-7403
- OpenAlex
- W1986734957
- Cited by
- 101
- References
- 17
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comorbidities in Cushing’s disease. https://app.cochat.ai/papers/10.1007/s11102-015-0645-6
- The paper
- Sharma, S. T., Nieman, L. K., & Feelders, R. A. (2015). Comorbidities in Cushing’s disease. Pituitary. https://doi.org/10.1007/s11102-015-0645-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.